肺癌患者肺部真菌感染应用伏立康唑联合康艾注射液治疗的疗效观察  

Efficacy of voriconazole combined with Kang'ai injection in the treatment of pulmonary fungal infections in lung cancer patients

作　　者：孙远南 陆明荣 倪慧[1,2] 赵玉华[1,2] 方红明[1,2] 

机构地区：[1]浙江萧山医院药剂科,浙江萧山311201 [2]浙江萧山医院肿瘤内科,浙江萧山311201

出　　处：《中华医院感染学杂志》2015年第23期5377-5379,共3页Chinese Journal of Nosocomiology

基　　金：浙江省卫生厅基金资助项目(14077-01)

摘　　要：目的探讨肺癌患者肺部真菌感染应用伏立康唑联合康艾注射液治疗的疗效,为临床治疗提供参考依据。方法选取2013年5月-2015年5月医院收治的肺癌合并肺部真菌感染患者84例进行研究,按照入院顺序分为观察组和对照组各42例,对照组给予伏立康唑进行治疗,观察组在此基础上联合康艾注射液进行治疗,比较两组患者临床资料及疗效,数据采用SPSS 18.0软件进行统计分析。结果观察组在体温恢复时间、白细胞恢复时间、住院时间分别为(3.6±1.7)(7.4±3.6)(15.2±3.6)d,均短于对照组的(5.2±2.9)(8.9±2.1)(19.8±4.5)d;对比两组患者治疗后的真菌清除情况,观察组的真菌清除率为97.62%,明显高于对照组的38.10%;观察组患者治疗总有效率为88.10%,明显高于对照组的50.00%,差异均有统计学意义(P<0.05)。结论伏立康唑联合康艾注射液治疗肺癌患者肺部真菌感染疗效显著,在改善患者机体功能的同时,缩短患者住院时间,值得广泛推广应用。OBJECTIVE To investigate the application of voriconazole combined with Kang＇ai injection in the treat- ment of pulmonary fungal infections in patients with lung cancer so as to provide references for clinical treatments. METHODS From May 2013 to May 2015, 84 lung cancer patients with pulmonary fungi infections were studied. According to the the admission time, they were randomly divided into observation group and control group with 42 cases each. The control group was treated with voriconazole, while the observation groups received Kang＇ai infec- tions in addition to this. The clinical data and efficacy of the two group were compared. All data were statistically analyzed by SPSS 18.0 software. RESULTS The body temperature recovery time was （3.6 ±1.7） d in the obser- vation group and leukocyte recovery time was （7.4±3.6） d and length of hospital stay was （15.2±3.6） d, sig- nificeatly shorter than the control group of （5.25±2.9）, （8.9±2.1）, （19.8±4.5） d, （P〈0.05） ; fungal clear- ance rates was 97.62% in the observation group, significantly higher than the control group of 38.10%. In addi- tion, the total effective rate of the observation group was 88. 10% in the observation group, remarkably higher than that of the control group （50.00%）. The differences were significant （P〈0.05）. CONCLUSION Voricon- azole combined with Kang＇ai injection therapy have remarkable clinical effect in treating pulmonary fungal infections in patients with lung cancer in improving the patient＇s body function and shorten hospital stay and it can be promo- ted widely in clinical practice.

关 键 词：肺癌 肺部真菌感染 伏立康唑 康艾注射液 临床疗效 

分 类 号：R978.1[医药卫生—药品]